ISSN 2395-650X

International Journal of Life Sciences Biotechnology Pharma Sciences

E-mail: editorijlbps@gmail.com editor@ijlbps.org

International Journal of Life Sciences Biotechnology Pharma Sciences

Volume 7 Issue1,March2019

Non transferrin thalassemia patients may now have their bound iron estimated using a simple, quick, and improved colorimetric technique.

K. Nagur Babu

Abstract

Iron in the plasma that is not attached to the protein transferrin, which normally carries it, is referred to as "non transferrin bound iron." It has been hypothesized that the redox activity of such iron compounds, as shown by Haiber weiss and Fenton chemistry, makes them poisonous. Non transferrin bound iron has been the subject of much research in patients receiving blood transfusions for the treatment of iron overload disorders such as hemochromatosis and thalassemia. Several academics have proposed studying NTBI to evaluate the usefulness of chelators in treating iron excess. Different researchers have proposed different ways for measuring the amount of iron that is not bound to transferrin, such as chromatography, fluorimetry, atomic absorption spectroscopy, spectrophotometry, etc. The considerable complexity of the process, the need for expensive specialized equipment and accessories, and the questionable dependability mean that none of them is still universally recognized or regarded gold standard. In order to make the bathophenanthroline based colorimetric approach for non transferrin bound iron measurement accessible to smaller labs with less resources without sacrificing accuracy, we have experimented with a number of alternative variants. NTBI values were calculated for both -thalassemia patients and healthy controls using the trial methodology that yielded the most stable findings. We discovered that the background noise was much reduced and the most consistent findings were produced by high-speed centrifugation with interstitial sample pre-incubation. There was a statistically significant difference between the means of the thalassemia patient group and the control group for the quantity of non-transferrin bound iron.Hemochromatosis, beta thalassemia, and bathophenanthroline are all diseases associated with an excess of iron that isn't bound to transferrin.

Introduction

Although iron is a necessary transitional metal that serves various important functions in the body, too much of it or iron in its free form may be harmful. Because it can go back and forth between its ferric (Fe3+) and ferrous (Fe2+) ionic states, it may produce reactive oxygen species via Haiber weiss and Fenton chemistry1, 2, 3. This is the primary cause of its toxicity. This quality mostly manifests when iron is allowed to exist in its free state, without the classically protecting carrier molecule Transferrin (Tf). Non transferrin bound iron (NTBI4) is a common term for this kind of iron. Nonetheless, it is fundamentally distinct from ferritin and haem and does not include apo-Tf. Normally, there wouldn't be any free iron floating about since the concentration of Tf would be high enough to occupy all the iron in the plasma. Due to this understanding, the NTBI was firstly checked for and detected in the patients with thalassemia followed by the patients suffering from hemochromatosis as a simple spill over mechanism[5]. However later studies suggest the existence of such free iron in the conditions which are not linked with iron overload

Department of Pharmacology, C. L. Baid Metha College of Pharmacy, Chennai, (T.N.) - India 2, Department of Pharmacology

Even though being devoid of traditional carrier the iron can't really exist in absolutely free form, rather it is suggested to be bound with a numerous negatively charged molecules like albumin, citrate, DNA, acetate etc.[13,14,15]. As this fraction is not bound with Tf, it can escape the strict iron regulatory mechanism which is mainly focused on Tf bound iron and consequently get deposited intracellularly and cause the damage of the respective organ. NTBI is suggested to cause damage to heart, pancreas, liver, endocrine glands etc. The main way through which iron damage the organ free radical generation, which act detrimentally by depolymerising

polysaccharide, inactivating enzymes, lipid peroxidation and damaging DNA[16,17]. Such deleterious effects are combated by Tf which binds to iron and cover its redox activity along with other anti oxidants like vitamin E, glutathione, bilirubin, urate etc.[18,19,20,21,22]. This free fraction of iron as a whole or its sub fraction is named differently by various researchers e.g. Labile plasma iron (LPI), Catalytic iron, free iron, redox active iron, NTBI, Non Plasma bound iron (NPBI), BDI (Bleomycin Detectable Iron), chelatable iron etc. depending on its biological characteristics or its accessibility to various chelators. Presently NTBI is suggested to be analyzed mainly for evaluation of iron overload and the efficacy of the chelator in such patients. However it is also found diagnostically significant in myocardial infarction, renal disease, diabetes, liver disease etc.[6,7,8,9,10,11,12]. Presence of NTBI in non iron loaded condition have open the way for its wide scale indications in future, especially in diseases where oxidative stress plays an important role. Even after probable wide scale applications in diagnosis and prognosis of disease, no gold standard or even universally accepted method for NTBI estimation is available[23].

Several methods have been experimented by researchers to estimate NTBI, which are either based on indirect determination of NTBI with the help of Bleomycin or direct chelation of NTBI and its estimation with or without separating it from the biological fluid. Bleomycin based method is the oldest one but lengthy, tedious and extremely vulnerable to various factors like pH, source of bleomycin and application of chelax powder to minimize non specific iron interference increase the cost and complexity. The chelator based assays use different chelators to catch hold NTBI iron which is then either separated from the biological fluid usually by ultrafiltration and estimated with various analytical approaches like HPLC, atomic absorption spectroscopy, inductive conductiometric plasma spectrometry, and colorimetry or measured directly with fluorimeter without separation[24]. The fluorescent based methods are comparatively rapid and require least technical efforts but demand a specialized instrument fluorimeter, which may restrict its applicability. Chelation based methods exploring the ultrafiltration step to take off NTBI fraction from the biological fluid requires higher sample volume and the customized demand depending on the specialized detection system.

Amongst all we have look forward for the method which is least demanding and favorable to be opted in laboratories with restricted resources. One such method was suggested by Zang et al which is based on colorimetric estimation of NTBI with the use of Bathophenanthroline (BPS) as a chromogen, it was modulated by Nilsson et al who suggested the use BPS as a chelator as well as chromogen[13,25]. BPS has been used as a key ingredient in these methods which traces the forms of NTBI reacting with it. This BPS detectable portion may or may not be complete NTBI portion due to the heterogenicity of NTBI fractions reported by researchers[26].

β thalassemia major is an inherited autosomal disorder of hemoglobin synthesis, wherein the impairment of β chain synthesis takes place. It results in moderate to severe anemia and such patients are treated with frequent blood transfusions. Due to the frequent blood inflow these patients are susceptible to the development of situation like iron overload which may increase the transferrin saturation and may exhibit the presence of NTBI.

We have experimented certain variations in colorimetric method to make it simple, rapid and user friendly so that it can be applied in routine clinical practice[13]. After achieving the reasonably reliable results, we have analyzed the β thalassemia major patient samples for NTBI, serum total iron, % transferrin saturation and Total Iron Binding capacity (TIBC). An attempt has been made to derive the correlation of the NTBI with the other iron related parameters studied.

Material and Methods

Study design

The present study was divided into two phases.

In the phase1, various tools available in the medium scale laboratories were experimentally explored to increase the ease, simplicity and speed of the method without compromising the reliability of the results.

In the phase 2 of the study, healthy controls and the clinical case groups were analyzed for the presence andchange in the levels of NTBI. The correlation of NTBI with the other analytes was evaluated.

Subjects

Blood samples were collected from 365 subjects forthis study. Out of these 345 were apparently healthy subjects and 20 were known cases of β thalassemia major. From 345 apparently healthy subjects 290 subjects sample were studied for various experimental trials, 55 were taken as control group.

Controls

This group consist of 55 apparently healthy human adults of the age group 18-50 years, who were either regular blood donors or attendants of patients, staff members and others from south Gujarat region. Cases

β Thalassemia major patients of south Gujarat region undergoing blood transfusion therapy have been included.

Informed consent was obtained from all the subjects included.

Sampling

In all the cases blood sample were collected by venipuncture.

Types of sample and anticoagulant

In phase 1 of the study, blood sample were collected in either heparinised or plain Vacutainer® with or without gel separator as per protocol design.

In the phase 2 of the study, the samples were collected in plain Vacutainer®.

Storage of the sample

All the samples collected with or without anticoagulant were centrifuged at 2000 rpm for 15 minutes at end of 30 minutes of collection. All the samples were either processed within next 4 hours or stored within 4 hour of the collection at -55 ^{0}C, till the time of processing, but not more than 3 months.

Biochemical parameters

NTBI, total serum iron, TIBC, % Transferrin saturation.

Materials required

Chemicals and consumables

All chemicals used were of analytical grade and of highest purity available. 4,7-diphenyl-1,10-phenantroline disulphonate (bathophenanthroline disulphonate) (BPS) (B 1375) and ferrous ammonium sulphate [(NH4)2Fe(SO4)2] (F 3754) were purchased from Sigma Aldrich chemical company. Ascorbic acid (103033E) was purchased from BDH Laboratory. De- ionized water was produced from Mili Q water purification system and used freshly. Four different types of BD Vacutainer® s were used as follows

a. Heparinised Vacutainer® without gel separator
b. Heparinised Vacutainer® with gel separator
c. Plain Vacutainer® with gel separator
d. Plain Vacutainer® without gel separator

All tubes and accessories used were disposable and made up of polystyrene to minimize iron interference. The syringe filter used was PVDF durapore membrane of 0.45 µ porosity (SLHVO33RS) from Millipore.

Instruments

High speed centrifugation was done with Revolutionary high speed table top refrigerated centrifuge of Remi, with R-248 rotor; the absorbance was measured with Spectroscan uv 2700 double beam uv-visible spectrophotometer of Chemitro.

Standard curve

Standard curve was prepared with 1 mM BPS and a graded concentration i.e. 0.1-25.6 µmol of iron prepared from ferrous ammonium sulfate, without areducing reagent ascorbate. After mixing the ferrous ions and BPS, the mixture was incubated for 15 minutes at room temperature to ensure completion of the reaction. After incubation the absorbance were read at 535 nm against water blank.

At the experimental level another standard curve was plotted in the same manner but with 1mM ascorbate.

Method

Methodology for phase I: Experimental protocol The experimentation includes 6 trials operated in asequential manner.

Trial 1: Blood samples were collected in heparinised Vacutainer® without gel

separator; plasma was separated by centrifuging the Vacutainer® at 2000 rpmfor 15 minutes and processed in two different ways as follows:

- Plasma was filtered with filter mentioned in the materials and method before the reaction.
- Plasma was processed and after the reaction atthe end of incubation period just before colorimetric reading the reaction mixture was filtered with the filter mentioned in the material and method.

Trial 2: Blood samples were collected in heparinised Vacutainer® without gel separator, plasma was separated as in trial 1 and processed in three different ways as follows:

- Plasma was re-centrifuged at 2500 rpm for 15 minutes and vortex mixed twice i.e. before the reaction and at the end of reaction before readingthe absorbance.
- Plasma was re-centrifuged at 2500 rpm for 15 minutes and absorbance was read at the end of reaction without application of vortex mixture.
- Plasma was processed and read without application of low speed re-centrifugation andvortex mixture.

Trial 3: Blood samples were collected in heparinised Vacutainer® with gel separator, plasma was separated as in trial 1 and processed in two different ways as follows:

- Plasma was processed and after the reaction at the end of the incubation period just before the colorimetric reading the reaction mixture was filtered with the syringe filter mentioned in the materials and method.

Plasma was processed with the regular protocol without application of filter. **Trial 4:** Blood samples were collected in plain Vacutainer® without gel separator. Serum was separated by centrifuging the Vacutainer® at 2000 rpmfor 15 minutes and processed in two different ways as follows:

- Serum was filtered with the filter mentioned in materials and method before the reaction and absorbance was taken at the end of reaction.
- Serum was processed and after the reaction at the end of incubation period just before colorimetric reading the reaction mixture was filtered with the filter mentioned in materials and method.

Trial 5: Blood samples were collected in plain Vacutainer® without gel separator; serum was separated as in trial 4 and processed in three different ways as follows:

- Serum was re-centrifuged at 10,000 rpm for 30 minutes. Using a micropipette, the clear bottom portion of serum was transferred cautiously to another tube. An extra care has been taken to minimize the disturbance of top fatty layer formed at the end of high speed centrifugation. The separated clear portion of serum then pre incubated at 37 ^{0} C for 15 minutes and processed with regular protocol.
- Serum was re-centrifuged at 10,000 rpm for 30 minutes. Using a micropipette, the clear bottom portion of serum was transferred cautiously to another tube. An extra care has been taken to minimize the disturbance of top fatty layer formed at the end of high speed centrifugation. The separated clear portion of serum thenprocessed with regular protocol without in between sample pre incubation.
- The serum samples were processed regularly without high speed centrifugation and pre incubation.

Trial 6: Blood samples were collected in plain Vacutainer® with gel separator. Serum was separated as in trial 4 and processed in three different ways as follows:

- Serum was re-centrifuged at 10,000 rpm for 30 minutes. Using a micropipette, the clear bottom portion of serum was transferred cautiously to another tube. An extra care has been taken to minimize the disturbance of top fatty layer formed at the end of high speed centrifugation. The separated clear portion of serum was then pre incubated at 37 ^{0} C for 15 minutes and processed with regular protocol.

  Serum was re-centrifuged at 10,000 rpm for 30 minutes. Using a micropipette, the clear bottom portion of serum was transferred cautiously to another tube. An extra care has been taken to minimize the disturbance of top fatty layer formed at the end of high speed centrifugation. The separated clear portion of serum was then processed with regular protocol without in between sample pre incubation.
- The serum samples were processed without high speed centrifugation and pre incubation.

Figure 1: Experimental flow chart: shows all the experimental trials in brief.

Estimation of NTBI in serum/plasma

Phase 1:

Heparinized plasma / serum were processed with the specification noted in the experimental trials. To evaluate the consistency of results for each and every trial sample was processed in duplicate.

Phase 1 and 2:

Color was developed by mixing sample with BPS and ascorbate 1mM each in final reaction mixture. 1mM Ascorbate was added along with BPS which can convert the ferric ions to ferrous ions which then react with BPS and generate the colored end product. The reaction mixture was then mixed and incubated for 10 min. at R.T. and read as test at 535 nm against reagent blank which is aqueous solution of BPS and Ascorbate 1mM each. For each and every sample, the sample blank was placed without BPS and ascorbate. The value of each sample blank and reagent blank were subtracted from value of test.

Methodology for phase 2

NTBI was measured from control and cases as per experimental trial no 5A. In the samples collected from the subjects with β thalassemia, serum iron, TIBC and

% Tf saturation were analyzed.

Statistical analysis

SPSS 15 was used for box plotting the graphs and for descriptive analysis.

Results and Discussion

Colorimetric analysis of NTBI has been experimented by good number of research workers with the chromogen BPS. BPS is a bidentate ligand and best suitable for quantification of micro level of iron. Zang et al suggested to use the same chromogen for estimation of NTBI in biological sample along with an extra mobilizer, which chelates iron and then it can be estimated colorimetrically with the help of chromogen BPS[25]. Nilsson et al suggested of using BPS all aloneas it can play the dual role of chelator and chromogen[13]. This modification facilitates decrease in the assay time and reduction in the complexity of the procedure to a great extent. But the major limitation of this protocol was the high and fluctuating background color at 535 nm at which the absorbance has to be taken. They further suggested of using the multiscreen filtration system to minimize this background noise, which is not feasible to be used in routine pathological laboratories or hospital setups.

We have carried out experiments on the various routinely available techniques as shown in the experimental trial to minimize the non specific absorbance. One more significant modification we have done in the test protocol is the addition of 1mM ascorbate to the test mixture, which can convert ferric forms of iron to ferrous form and generate color with BPS. This modification has been done to estimate the level of total free iron (ferric + ferrous), and not only ferrous form. As in the body the conversion of ferric form to ferrous form takes place in the presence of reducing agents and ultimately leads to the generation of free radicals triggering the pathological events. No effect of the ascorbate on final color generation was ensured by making two standard curves with various aqueous dilutions of ferrous ammonium sulphate and BPS with and without ascorbate (data not given).

For aqueous solution, the linearity of the method was 0.1-50 µmol iron. The detection limit of the method is

0.1 µmol, which is comparable with the respective values reported by other workers using different methodology[27,28]. Below this level the corresponding absorbance became undetectable. Sensitivity of the spectrophotometer is extremely essential in this case; we had increased the path length which was of 10 mm, to enhance the sensitivity of the method. However while doing so the volume of sample demand had also been increased.

A summary of results for various trials experimented has been presented in the form of descriptive analysis table 1, which shows minimum, maximum, mean and standard deviation of NTBI. Vortex mixing and low speed re-centrifugation of the sample had been experimented to minimize the fluctuation in the absorbance but they failed to do so. Filtration of the sample is a routinely experimented technique which can increase the visible clearness and uniformity of the sample and thus can minimize the non specific fluctuation in absorbance. PVDF filter were used, which was already been successfully utilized by some other research workers in some other format for NTBI estimation[13]. In this study, we have used the PVDF filter in syringe format which is easily available, cost effective and doesn't need specialized accessories. As shown in the protocol, sample had been filtered boththe ways i.e. before and after reaction; unexpectedly the results exhibited a vast fluctuation in both the cases. This could be some non specific reaction

taking place in reaction mixture when it comes in contact with either the filter or the accessories used. As compared tothe protocol including filtration, we found lesser fluctuation in the absorbance when samples were processed without filtration, so the remaining protocolswere designed without filtration step. In another trial, gel Vacutainer®s were used to minimize the fluctuation, which could not decrease the fluctuation in the absorbance, but certainly increased the serum/plasma volume output from the sample, which is also significant in this methodology. High speed filtration has been routinely practiced to minimize the non specific turbidity of the sample which has been tried in our experiment to minimize the non specific absorbance. Freshly collected samples after separation of serum or freshly frozen and stored serum samples were thaw and then re-centrifuged at high speed at 10,000 rpm for 30 minutes. An extra care has been taken to minimize the disturbance of top fatty layer formed at the end of high speed centrifugation. This approach had significantly reduced the non specific fluctuation and generated more consistent results. Another modification in the same approach has been successfully incorporated i.e. in between sample pre incubation at 37^0 C. Experimentally it has been shown that when sample is processed for electrophoresis, the mobility of the lipoproteins can enhanced when sampleis pre-incubated at 37^0 C[29]. This was suggested to be due to solubilization of the lipoproteins present in the sample by activating LCAT enzyme. The same approach was tried in the present methodology as solubilization of lipoprotein may also decrease the non specific fluctuation in the absorbance. In the final protocol the samples were pre incubated after high speed centrifugation, where the major lipidic portion had been removed by high speed centrifugation and a little part present in the sample were made more soluble which gave the most consistent and reliable results. Results of the experimental trials operated in duplicates showed maximum consistency with the trial no 5A and 6A (results had not been shown). The serum has been suggested over plasma as the test samples due to obvious greater and long lasting apparent clearness and ease of collection, when the value of the analyte was suggested to be same in both.

The mean NTBI value for control group was 0.02 $\pm$ 0.06 µmol, which is comparable with the other methodology[11,27,30]. The significant cut off value we setwas $\leq$ 0.3 µmol, which was the highest value found in control group, no control subject had the respectivevalue > 0.3 µmol. The mean NTBI values for β thalassemia major patients were higher than the respective mean derived in the control group. When the mean $\pm$ SD was checked with the other clinical We did find a link between NTBI and serum total iron (r = 0.7) and % Tf saturation (r = 0.55), however we discovered no association between NTBI and TIBC (r = 0.15). Patients with thalassemia major had NTBI values that varied from 0 to 1.6 mol. With mean values of 0.61 + 0.54 mol, the experimental group outperformed the control group by a statistically significant margin (p 0.001). While some have reported higher levels for NTBI, the mean value we found in individuals with thalassemia major is lower. Direct measurement of NTBI, without application of the additional mobilizor that may extract the iron even from the other iron bound ligands that can't release iron on binding with BPS, may explain the lower trend of the findings in the current work.

We conclude that high-speed centrifugation followed by sample pre-incubation may more effectively eliminate non-specific background noise and provide reliable findings. This straightforward method has the potential to be a financially viable adaptation for colorimetric assessment of NTBI in medical settings like pathology labs and hospitals. Our control group NTBI value is consistent with that reported by other workers with similar sensitivity. We discovered that the mean NTBI in patients with thalassemia using the current approach was greater than in the control group but lower than in the same patient group utilizing a different methodology.

References

1. Chau L. (2000). Iron and atherosclerosis. Proceedings of the national science council. Republic of China—Part B. Life Sci., 24:151– 5.
2. Meyers D.G. (2000). The iron hypothesis: Does iron play a role in atherosclerosis? Transfusion, 40:1023–9.
3. Gackowski D., Kruszewski M., Jawien A., Ciecierski M., Olinski R. (2001). Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med.,

31:542–7.

4. Breuer W., Cabantchik Z.I. (2001). A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem., 299:194–202. Bonsdorff L.V. (2002). American association of Cli. Chem., 48:307-14.
5. Lee D.H., Liu D.Y., Jacob D.R., Hai-Rim Shin J.R., Song K., Lee I. et al. (2006). Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care, 29:1090–5.
6. Halliwell B., Aruoma O.I., Mufti G., Bomford A. (1988). Bleomycin detectable iron in serum from leukaemic patients before and after chemtherapy. Therapeutic implications for treatment with oxidant-generating drugs. FEBSLett., 241:202–4.
7. Carmine T.C., Evans P., Bruchelt G., Evans R., Handretinger R., Niethammer D., et al. (1995). Presence of iron catalytic for free radical reactions in patients undergoing chemtherapy: implications for therapeutic management. Cancer Lett., 94:219–26.
8. Du¨rken M., Nielsen P., Knobel S., Finckh B., Herrnring C., Dresow B., et al. (1997). Non- transferrin-bound iron in serumof patients receiving bone marrow transplants. Free Rad Biol Med., 22:1159–63.
9. Bradley S.J., Gosriwatana I., Srichairatanakool S., Hider R.C., Porter J.B. (1997). Non- transferrin-bound iron induced by myeloablative chemtherapy. Br J Haematol., 99:337–43.
10. Lele S., Shah S., McCullough P.A., Rajapurkar M. (2009). Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention, Aug;5(3):336-
42. PubMed PMID: 19736158.
11. Harrison-Findik D.D., Klein E., Crist C., EvansJ., Timchenko N., Gollan J. (2007). Iron- mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology, 46:1979–85.
12. Nilsson U.A., Bassen M., Sa¨vman K., Kjellmer I. (2002). A simple and rapid method for the determination of ‘‘free’’ iron in biological fluids. Free Radic Res., 36:677–84.
13. Lovstad R.A. (1993). Interaction of serum albumin with the Fe(III)- citrate complex. Int J Biochem., 25:1015–7.

- Grootveld M., Bell J.D., Halliwell B., Aruoma O.I., Bomford A., Sadler P.J. (1989). Non- transferrin bound iron in plasma or serum frompatients with idiopathic hemochromatosis. J. BiolChem., 264:4417–22.